Results 191 to 200 of about 37,805 (220)

Tumour-reactive heterotypic CD8 T cell clusters from clinical samples. [PDF]

Nature
Ibáñez-Molero S, Veldman J, Simon Nieto J, Traets JJH, George A, Hoefakker K, Karomi A, Harkes R, van den Broek B, Pack SM, Tas L, Visser NL, van Hal-van Veen SE, Alóndiga-Mérida P, Alkemade M, Seignette IM, Tissier R, Nieuwland M, van Baalen M, Poźniak J, Mul E, Tol S, Stenqvist S, Nilsson LM, Nilsson JA, Haanen JBAG, van Houdt WJ, Peeper DS.   +27 more
europepmc   +1 more source

miR‑27b‑3p modulates CD4+CD39+ Tregs to drive immune‑mediated intervertebraldisc degeneration. [PDF]

Int J Mol Med
Li Q, Zhao C, Jin P, Shen C.
europepmc   +1 more source

Immune cell signatures and preeclampsia: Unveiling causal links through genome-wide association studies. [PDF]

Medicine (Baltimore)
Zhang H, Zu Y, Xiu X, Yi H, Xu X, Yan J.
europepmc   +1 more source

Purinergic Modulation and CD39/ENTPD1 in Cancer [PDF]

, 2014
openaire   +1 more source

Immune cells mediated the causal relationship between gut microbiota and carpal tunnel syndrome: A Mendelian randomization study. [PDF]

Medicine (Baltimore)
Li JA, Zhou CH, Shen R, Xiao HD, Guo HB, Liang JY, Zhang Y.   +6 more
europepmc   +1 more source

Bottom-Up Synthesis and Purification of Extracellular Vesicle Mimetics. [PDF]

J Extracell Vesicles
van de Schepop L, Stiemsma YL, Wichers LX, Hotting ES, Smits S, Seinen CW, Edelbacher TV, Barendrecht AD, van Wesel ACW, Schiffelers RM, Vader P.   +10 more
europepmc   +1 more source

The purinergic signaling interfaces in breast cancer angiogenesis. [PDF]

Purinergic Signal
da Silva FC, Stabile J, Fürstenau CR, Araújo TG.   +3 more
europepmc   +1 more source

Neutrophil-T cell cross talk in noninfectious liver diseases. [PDF]

Am J Physiol Gastrointest Liver Physiol
Gromova B, Kupcova V, Longhi MS, Gardlik R.   +3 more
europepmc   +1 more source

Crosstalk Between Extracellular Vesicles and Regulatory T Cells Across Cancers: From Interaction to Therapeutic Potential. [PDF]

Int J Nanomedicine
Liu D, Hao Z, He G, Huang Y.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Targeting CD39 in cancer

Nature Reviews Immunology, 2020
The ATP-adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumour microenvironment. Consequently, multiple clinical strategies are being explored to target this pathway for the treatment of cancer; in particular, recent clinical data with CD73 antagonists and inhibitors of A2A receptors have demonstrated the ...
Achim K. Moesta, Xian-Yang Li, Mark J. Smyth   +2 more
openaire   +3 more sources